Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific looks like a high-quality business, but the current valuation already relies significantly on strong market expectations. In terms of earnings, the company shows resilience: net income, operating income, EBITDA, and EPS remain high, while net profit margin and operating margin are holding at solid levels and look better than the industry median. At the same time, the efficiency trend is not accelerating: ROE, ROA, and ROI are gradually declining year by year, which suggests that growth in capital and assets is not translating into a comparable improvement in returns. Valuation multiples remain elevated relative to the industry: P/E, P/S, P/B, and especially P/FCF are above the median, and this limits the potential for further multiple expansion without a new acceleration in growth. An additional restraining factor is the increase in debt burden: debt/equity is above the industry level and has increased over the year, long-term debt has also risen noticeably, and total liabilities continue to grow faster than equity. Liquidity does not look weak, but the current ratio and quick ratio are below industry benchmarks and have deteriorated compared with stronger levels last year. This means the company has a cushion, but not one that is comfortable enough to fully offset debt and valuation risk. The strengths remain the scale of the business, high revenue, positive earnings momentum, and stable margins, which support fundamental resilience. The weakness is the lack of a clear improvement in capital efficiency and the expensive valuation across most key multiples. Dividend yield is practically nonexistent, so investors receive almost all of their return through price appreciation rather than cash payouts. Overall, the fundamentals support a moderately positive view of the company, but do not justify an aggressive increase in the target price. For an investor, this is a story of a high-quality but no longer cheap leader, where upside potential exists, but it is constrained by a high valuation base and rising debt load.

Thermo Fisher Scientific Inc

Средний индекс, значительно вырос. Быки в растерянности.

Medium index, significantly up. The bulls are confused.

Сильный индекс, без изменений. Рынок на стороне быков.

Strong index, flat. The market is on the bulls' side.

Слабый индекс, незначительно упал

TMO has strong profitability and stable margins, but its valuation is expensive, debt is increasing, and liquidity and return on capital are gradually weakening.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $316.2 million dollar inflow -- that's a 9.9% increase week over week in outstanding units (from 45,400,000 to 49,900,000). Among the largest underlying components of IYH, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.2%, Abbott Laboratories (Symbol: ABT) is up about 1.9%, and Danaher Corp (Symbol: DHR) is higher by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $53.935 per share, with $70.78 as the 52 week high point — that compares with a last trade of $70.42. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further IYH Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Inflows: IYH, TMO, ABT, DHR

Last Friday, the three major Wall Street indexes closed a losing week. The Dow Jones Industrial Average slipped 0.4% for its third consecutive weekly decline, while the S&P 500 fell 0.6% and the Nasdaq Composite declined 2%, marking a second straight weekly loss for both indexes.
Stocks were pressured by a technology-led selloff after quarterly results from Alphabet and Tesla reignited concerns over heavy AI-related spending and stretched valuations. The weakness in semiconductor shares dragged the Nasdaq sharply lower, overshadowing upbeat earnings from several other companies.
Investor sentiment was also weighed down by escalating U.S.-Iran tensions that pushed oil prices sharply higher for much of the week, fresh tariff announcements from the Trump administration and uncertainty over the Fed's interest-rate path ahead of its policy meeting, keeping risk appetite in check.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Hinge Health and Usio Surge Following Zacks Rank Upgrade
Shares of Hinge Health, Inc. HNGE have gained 34.6% (versus the S&P 500’s 0.1% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on May 13.
Another stock, Usio, Inc. USIO, which was upgraded to a Zacks Rank #2 (Buy) on May 18, has returned 27% (versus the S&P 500’s 0.01% fall) since then.
A portfolio of Zacks # 1 Rank (Strong Buy) stocks has outperformed the S&P 500 index by 5.7 percentage points this year. Through July 6th this year, the Zacks # 1 Rank portfolio returned +15.3%, which compares to a +9.7% gain for the S&P 500 index and a +12.6% gain for the equal-weight version of the index in the same time period.
Since its inception in 1988, this portfolio of Zacks # 1 Rank stocks has outperformed the market by 12.4 percentage points. The average annual return for this portfolio of Zacks # 1 Rank stocks since inception in 1988 was +23.9% through July 6th, which compared to a +11.6% gain for the S&P 500 index and a +11.4% gain for the equal-weight version of the index.
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Northern Trust and West Pharmaceutical
Shares of Northern Trust Corporation NTRS and West Pharmaceutical Services, Inc. WST have surged 12.1% (versus the S&P 500’s 0.1% fall) and 5.2% (versus the S&P 500’s 0.1% rise), since their Zacks Recommendation was upgraded to Outperform on May 12 and May 13, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Micron, Advanced Micro Devices Shoot Up
Shares of Micron Technology MU, which belongs to the Zacks Focus List, have gained 85.4% over the past 12 weeks. The stock was added to the Focus List on December 27, 2016. Another Focus-List holding, Advanced Micro Devices, Inc. AMD, which was added to the list on May 19, 2025, has returned 50.1% over the past 12 weeks. The S&P 500 has advanced 3.5% over this period.
The 50-stock Focus List portfolio returned +13.12% in the first half of 2026 (through June 30th, 2026) vs. +10.21% for the S&P 500 index and +12.14% for the equal-weight version of the index.
The portfolio returned +22.1% in 2025 vs. +17.9% for the S&P 500 index and +11.4% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
Through June 30th 2026, the portfolio’s rolling returns on a one-year, three-year, five-year, ten-year, and since 2004 have been +26.93% (vs. +22.33% for the S&P 500 index), +22.23% (vs. +20.62%), +12.80% (vs. +13.41%), +16.65% (vs. +15.51%) and +12.48% vs. (+10.94%), respectively.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Thermo Fisher & Monster Beverage Gain Significantly
Thermo Fisher Scientific Inc. TMO, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 21% over the past 12 weeks. Monster Beverage Corporation MNST followed Thermo Fisher with 19.5% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned -9.4% in the first half of 2026 (through June 30th) vs. +10.2% for the S&P 500 index.
For 2025, the portfolio returned -1.67% vs. +17.9% gain for the S&P 500 index. For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF). In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks J. M. Smucker & 3M Company Outperform Peers
The J. M. Smucker Company SJM, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 23.2% over the past 12 weeks. Another ECDP stock, 3M Company MMM, has climbed 18.2% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -1.7% in the first half of 2026 (through June 30th) vs. +10.2% for the S&P 500 index and +9.03% for the Dividend Aristocrats ETF (NOBL).
The portfolio returned -0.6% in 2025 vs. a +6.8% gain for the Dividend Aristocrats ETF. For the full year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL. The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Carpenter Technology Delivers Solid Returns
Carpenter Technology Corporation CRS, from the Zacks Top 10 Stocks for 2025, has jumped 78.4% since January 5, 2026, compared with the S&P 500 Index’s 8.2% increase.
The Top 10 portfolio returned +26.83% in the first half of 2026 (through June 30th) vs. +9.97% for the S&P 500 index and +11.35% for the equal-weight version of the index.
The Top 10 portfolio returned +22.6% in 2025 vs. +17.9% for the S&P 500 index and +11.4% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Through the end of June 2026, the Top 10 portfolio has produced a cumulative return of +3,185.6% since 2012 vs. +629.1% for the S&P 500 index and +464.3% for the equal-weight version of the index. The portfolio has produced an average annual return of +26.9% in the period 2012 through June 30th, 2026 vs. +13.5% for the S&P 500 index and +11.2% for the equal-weight version of the index.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Beat the Market Like Zacks: Monster Beverage, Carpenter Tech, Usio in Focus

Thermo Fisher Scientific Inc.’s TMO shares jumped 8.7% after reporting second-quarter 2026 revenues of $11.99 billion, beating the Zacks Consensus Estimate of $11.68 billion.
Shares of Tesla, Inc. TSLA plunged 14.5% after reporting second-quarter 2026 earnings of 33 cents per share, missing the Zacks Consensus Estimate of 50 cents.
Union Pacific Corporation’s UNP shares gained 4% after reporting second-quarter 2026 revenues of $6.84 billion, beating the Zacks Consensus Estimate of $6.65 billion.
Shares of CSX Corporation CSX rose 5.8% after reporting second-quarter 2026 earnings of 54 cents per share, beating the Zacks Consensus Estimate of 50 cents.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CSX Corporation (CSX) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Company News for July 24, 2026

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

TMO Q2 2026 Earnings Call Transcript

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Deckers Outdoor Corp. (Symbol: DECK), where a total of 10,962 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 50.7% of DECK's average daily trading volume over the past month of 2.2 million shares. Especially high volume was seen for the $111 strike put option expiring July 24, 2026, with 1,976 contracts trading so far today, representing approximately 197,600 underlying shares of DECK. Below is a chart showing DECK's trailing twelve month trading history, with the $111 strike highlighted in orange:
Thermo Fisher Scientific Inc (Symbol: TMO) saw options trading volume of 10,583 contracts, representing approximately 1.1 million underlying shares or approximately 49.5% of TMO's average daily trading volume over the past month, of 2.1 million shares. Particularly high volume was seen for the $620 strike call option expiring August 21, 2026, with 1,050 contracts trading so far today, representing approximately 105,000 underlying shares of TMO. Below is a chart showing TMO's trailing twelve month trading history, with the $620 strike highlighted in orange:
And Expand Energy Corp (Symbol: EXE) options are showing a volume of 20,176 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 48.3% of EXE's average daily trading volume over the past month, of 4.2 million shares. Particularly high volume was seen for the $115 strike call option expiring September 18, 2026, with 7,440 contracts trading so far today, representing approximately 744,000 underlying shares of EXE. Below is a chart showing EXE's trailing twelve month trading history, with the $115 strike highlighted in orange:
For the various different available expirations for DECK options, TMO options, or EXE options, visit StockOptionsChannel.com.
Further DECK Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Thursday Option Activity: DECK, TMO, EXE

Thermo Fisher Scientific TMO delivered second-quarter 2026 adjusted earnings of $6.03 per share, up 13% year over year. The figure beat the Zacks Consensus Estimate by 5.6%.
Revenues rose 10% to $11.99 billion and surpassed the consensus mark by 2.67%. Results were supported by 5% organic revenue growth, while customer activity strengthened across the company’s end markets.
Following the earnings announcement, TMO stock rose 4.4% in pre-market trading today.
TMO's Segmental Growth Broadens
Life Sciences Solutions revenues increased 12.6% year over year to $2.82 billion. Segment income rose to $1.04 billion from $919 million, while the segment income margin expanded 20 basis points to 37%.
Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 11.6% to $6.69 billion. Segment income increased to $936 million from $825 million, and margin improved to 14% from 13.8%. The segment accounted for 55.8% of consolidated revenues before eliminations.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Analytical Instruments revenues advanced 6.9% to $1.85 billion. Segment income jumped to $424 million from $325 million, driving margin expansion to 23% from 18.8%. The improvement made this segment the strongest margin gainer in the quarter.
Specialty Diagnostics revenues grew 6.3% to $1.21 billion. Segment income reached $334 million compared with $306 million a year earlier, while margin increased to 27.7% from 27%. Together, the two smaller segments added growth without diluting overall operating profitability.
TMO Expands Operating Leverage
Adjusted operating income increased 15% year over year to $2.74 billion. The adjusted operating margin widened 90 basis points (bps) to 22.8%, reflecting stronger profitability across all four business segments.
On a GAAP basis, operating income rose 14% to $2.09 billion, while the operating margin improved 50 bps year over year. The cost of revenues was $7.05 billion, selling, general and administrative expenses were $1.91 billion, and research and development spending totaled $364 million.
Thermo Fisher’s Cash Deployment Reflects Strategic Moves
Thermo Fisher ended the second quarter with cash and cash equivalents of $4.06 billion compared with $3.25 billion at the end of the first quarter.
Cumulative net cash provided by operating activities came to $3.32 billion, compared with $2.12 billion in the year-ago period.
The company repurchased $1 billion of stock during the quarter and announced the divestiture of its microbiology business. For the first six months of 2026, acquisitions net of cash acquired totaled $8.87 billion, share repurchases reached $4 billion, and dividends paid amounted to $337 million.
Thermo Fisher Deepens Customer Partnerships
Thermo Fisher opened its flagship U.S. Bioprocess Design Center in Plainville, MA. The site expands its network of collaborative innovation hubs intended to help pharma and biotech customers accelerate drug development and optimize manufacturing.
The company also announced a collaboration with Precision Health Research, Singapore, to support the PRECISE-SG100K population health study. The project will use Thermo Fisher's integrated proteomics capabilities, including Olink technology and the Orbitrap Astral mass spectrometry system.
Our Take
Thermo Fisher ended the second quarter with both earnings and revenues beating respective estimates. Performance reflected the strength of the company’s proven growth strategy, strong execution and the power of the PPI Business System. Expansion of the adjusted operating margin in the quarter is also very promising.
During the quarter, Thermo Fisher launched a range of high-impact, innovative new products, including the next-generation Orbitrap mass spectrometry platforms with AI-driven analytics. It also introduced the Applied Biosystems PowerFlex Thermal Cycler to improve workflow flexibility, speed and reproducibility in molecular biology laboratories.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Danaher DHR and Elevance Health ELV.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Danaher, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.94, exceeding the Zacks Consensus Estimate by 5.44%. Revenues of $6.27 billion topped the Zacks Consensus Estimate by 2.88%.
DHR has an earnings yield of 4.7% compared to the industry’s 4.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.65%.
Elevance Health, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $7.45, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $49.8 billion outperformed the consensus mark by 0.8%.
ELV has an earnings yield of 6.9% compared to the industry’s 4.1% yield. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.65%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TMO Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

Thermo Fisher Scientific (TMO) reported $11.99 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 10.5%. EPS of $6.03 for the same period compares to $5.36 a year ago.
The reported revenue represents a surprise of +2.67% over the Zacks Consensus Estimate of $11.68 billion. With the consensus EPS estimate being $5.71, the EPS surprise was +5.6%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue Growth - Organic: 5% compared to the 3% average estimate based on five analysts.
Revenues- Laboratory Products and Biopharma Services: $6.69 billion versus the four-analyst average estimate of $6.46 billion. The reported number represents a year-over-year change of +11.6%.
Revenues- Specialty Diagnostics: $1.21 billion compared to the $1.17 billion average estimate based on four analysts. The reported number represents a change of +6.3% year over year.
Revenues- Life Sciences Solutions: $2.82 billion versus $2.74 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
Revenues- Eliminations: $-565 million compared to the $-522.03 million average estimate based on four analysts. The reported number represents a change of +12.8% year over year.
Revenues- Analytical Instruments: $1.85 billion compared to the $1.81 billion average estimate based on four analysts. The reported number represents a change of +6.9% year over year.
Shares of Thermo Fisher have returned +7% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Here's What Key Metrics Tell Us About Thermo Fisher (TMO) Q2 Earnings

(RTTNews) - Thermo Fisher Scientific (TMO) will host a conference call at 8:30 AM ET on July 23, 2026, to discuss Q2 26 earnings results.
To access the live webcast, log on to https://ir.thermofisher.com/investors/news-events/events/default.aspx
To listen to the call, dial (833) 461-5787 (US) or +1 (585) 542-9983 (International), Access code 835035800.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q2 26 Earnings Conference Call At 8:30 AM ET

(RTTNews) - Thermo Fisher Scientific (TMO) released a profit for its second quarter that Increases, from last year
The company's earnings totaled $1.736 billion, or $4.68 per share. This compares with $1.617 billion, or $4.28 per share, last year.
Excluding items, Thermo Fisher Scientific reported adjusted earnings of $2.241 billion or $6.03 per share for the period.
The company's revenue for the period rose 10.5% to $11.994 billion from $10.855 billion last year.
Thermo Fisher Scientific earnings at a glance (GAAP) :
-Earnings: $1.736 Bln. vs. $1.617 Bln. last year. -EPS: $4.68 vs. $4.28 last year. -Revenue: $11.994 Bln vs. $10.855 Bln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Q2 Income Climbs

The following companies are expected to report earnings prior to market open on 07/23/2026. Visit our Earnings Calendar for a full list of expected earnings releases.
RTX Corporation (RTX)is reporting for the quarter ending June 30, 2026. The aerospace and defense company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.66. This value represents a 6.41% increase compared to the same quarter last year. In the past year RTX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 17.11%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for RTX is 27.99 vs. an industry ratio of -0.70, implying that they will have a higher earnings growth than their competitors in the same industry.
T-Mobile US, Inc. (TMUS)is reporting for the quarter ending June 30, 2026. The wireless (national) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.52. This value represents a 11.27% decrease compared to the same quarter last year. In the past year TMUS has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 31.07%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for TMUS is 18.12 vs. an industry ratio of -7.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc (TMO)is reporting for the quarter ending June 30, 2026. The medical instruments company's consensus earnings per share forecast from the 8 analysts that follow the stock is $5.71. This value represents a 6.53% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 4.62%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for TMO is 21.07 vs. an industry ratio of 0.60, implying that they will have a higher earnings growth than their competitors in the same industry.
TotalEnergies SE (TTE)is reporting for the quarter ending June 30, 2026. The oil refining company's consensus earnings per share forecast from the 2 analysts that follow the stock is $3.07. This value represents a 95.54% increase compared to the same quarter last year. Zacks Investment Research reports that the 2026 Price to Earnings ratio for TTE is 8.02 vs. an industry ratio of 2.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Union Pacific Corporation (UNP)is reporting for the quarter ending June 30, 2026. The transportation (rail) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $3.20. This value represents a 5.61% increase compared to the same quarter last year. UNP missed the consensus earnings per share in the 4th calendar quarter of 2025 by -1.38%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for UNP is 23.23 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Lockheed Martin Corporation (LMT)is reporting for the quarter ending June 30, 2026. The aerospace and defense company's consensus earnings per share forecast from the 6 analysts that follow the stock is $7.22. This value represents a 0.96% decrease compared to the same quarter last year. LMT missed the consensus earnings per share in the 1st calendar quarter of 2026 by -3.45%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for LMT is 16.95 vs. an industry ratio of -0.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Blackstone Inc. (BX)is reporting for the quarter ending June 30, 2026. The financial services company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.32. This value represents a 9.09% increase compared to the same quarter last year. In the past year BX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 0.74%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for BX is 21.22 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Freeport-McMoran, Inc. (FCX)is reporting for the quarter ending June 30, 2026. The mining company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.60. This value represents a 11.11% increase compared to the same quarter last year. In the past year FCX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 21.28%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for FCX is 23.34 vs. an industry ratio of 30.50.
Comcast Corporation (CMCSA)is reporting for the quarter ending June 30, 2026. The cable tv company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.97. This value represents a 22.40% decrease compared to the same quarter last year. In the past year CMCSA has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 8.22%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for CMCSA is 6.84 vs. an industry ratio of 5.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Norfolk Southern Corporation (NSC)is reporting for the quarter ending June 30, 2026. The transportation (rail) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $3.23. This value represents a 1.82% decrease compared to the same quarter last year. In the past year NSC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 5.58%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for NSC is 27.07 vs. an industry ratio of 17.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Honeywell International Inc. (HON)is reporting for the quarter ending June 30, 2026. The diversified operations company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.80. This value represents a 67.27% decrease compared to the same quarter last year. In the past year HON has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.06%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for HON is 28.03 vs. an industry ratio of 11.40, implying that they will have a higher earnings growth than their competitors in the same industry.
argenx SE (ARGX)is reporting for the quarter ending June 30, 2026. The biomedical (gene) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $6.13. This value represents a 63.90% increase compared to the same quarter last year. In the past year ARGX has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.98%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for ARGX is 33.22 vs. an industry ratio of -13.30, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	28.94 21.49
Price/Sales	4.39 3.03
P/B	3.75 2.57
P/FCF	29.09 18.61

Indicator	TTM Median
ROE	13.24 19.43
ROA	6.40 6.99
ROI	7.88 9.91
Net Worth	196.37 0.21
Quick Ratio	1.15 1.79
Current Ratio	1.53 2.79

Indicator	TTM Median
Net Profit Margin	15.15 11.32
Operating Margin	17.47 14.11
Gross Margin	40.78 75.26
Return on tangible equity	0.00 44.85

Indicator	TTM Median
EPS	6.03 0.43
EPS Forecast	5.71 0.37
Revenue	11.01B 17.00M
Gross Profit	4.43B —
EBITDA	2.60B —

Thermo Fisher Scientific Inc

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue